Worldquant Millennium Advisors LLC Acquires Shares of 132,426 Charles River Laboratories International, Inc. (NYSE:CRL)

Worldquant Millennium Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 132,426 shares of the medical research company's stock, valued at approximately $24,446,000. Worldquant Millennium Advisors LLC owned 0.26% of Charles River Laboratories International at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. D1 Capital Partners L.P. purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $172,752,000. Norges Bank acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth approximately $98,886,000. Wellington Management Group LLP increased its position in shares of Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the last quarter. Nomura Holdings Inc. bought a new position in shares of Charles River Laboratories International during the fourth quarter worth about $56,820,000. Finally, Raymond James Financial Inc. acquired a new position in Charles River Laboratories International in the fourth quarter worth about $42,776,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on CRL. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective on the stock in a research note on Thursday, May 8th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $188.00 to $182.00 in a research note on Friday. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Finally, The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL traded up $1.16 during midday trading on Monday, reaching $136.76. 775,603 shares of the company traded hands, compared to its average volume of 993,966. The company has a market cap of $6.72 billion, a price-to-earnings ratio of 911.73, a PEG ratio of 4.54 and a beta of 1.50. The stock has a 50-day moving average price of $132.05 and a 200 day moving average price of $162.77. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.27 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).